Company news

Neurizon Therapeutics Limited news in 2026

Neurizon Therapeutics Limited's news releases, calls and decks from 2026, newest first.

View company

Bell Potter Healthcare Conference Presentation

November 18, 2026

Update - Proposed issue of securities - NUZ

November 15, 2026

Update - Proposed issue of securities - NUZ

November 15, 2026

Notice of General Meeting/Proxy Form

November 15, 2026

Prospectus

November 15, 2026

Share Purchase Plan and Options Offer Open

November 15, 2026

First Regimen I patient enters Active Treatment Extension

November 12, 2026

R&D Facility Extension and Second Drawdown Completed

November 12, 2026

Change in substantial holding

November 10, 2026

Section 708A Cleansing Statement

November 8, 2026

Application for quotation of securities - NUZ

November 8, 2026

Application for quotation of securities - NUZ

November 8, 2026

Application for quotation of securities - NUZ

November 5, 2026

Investor webinar reminder and presentation

November 4, 2026

Notification of cessation of securities - NUZ

November 1, 2026

Withdrawal of Resolution 4 from Notice of AGM

November 1, 2026

Redemption of all remaining Obsidian convertible notes

November 1, 2026

Proposed issue of securities - NUZ

November 1, 2026

Proposed issue of securities - NUZ

November 1, 2026

Firm commitments to raise A$4.3m and announcement of SPP

November 1, 2026

Trading Halt

October 28, 2026

Trading Halt

October 28, 2026

Appendix 4C & Quarterly Update

October 27, 2026

Appendix 4C & Quarterly Update

October 27, 2026

Notice of Annual General Meeting/Proxy Form

October 26, 2026

Change of AGM Date

October 22, 2026

Notification of cessation of securities - NUZ

October 13, 2026

Updated Investor Presentation and Webinar Reminder

October 6, 2026

FDA Type C Feedback, HEALEY trial potentially registrational

October 5, 2026

Dr Chris Bremer commences as Neurizon CEO

September 30, 2026

Change of Director's Interest Notice

September 16, 2026

Notification of cessation of securities - NUZ

September 15, 2026

Neurizon Announces Partial Redemption of Convertible Notes

September 9, 2026

Application for quotation of securities - NUZ

September 9, 2026

NIH funds Expanded Access Program for NUZ-001 in ALS

September 8, 2026

Neurizon Appoints Chief Executive Officer

September 6, 2026

Application for quotation of securities - NUZ

August 25, 2026

Appendix 4E and 2026 Annual Report

August 25, 2026

Appendix 4G and Corporate Governance Statement

August 25, 2026

Notification regarding unquoted securities - NUZ

August 24, 2026

Elanco representative appointed as Neurizon Board Observer

August 12, 2026

Neurizon Completes Initial Drawdown under R&D Facility

August 10, 2026

Neurizon Enters Strategic R&D Financing Facility

July 31, 2026

Appendix 4C & Quarterly Update

July 31, 2026

Melbourne investor briefing presentation

July 28, 2026

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

July 16, 2026

HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27

July 16, 2026

Neurizon executes long-term supply agreement with Elanco

June 16, 2026

HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule

June 11, 2026

HEALEY ALS Platform Trial Regimen I expands to 240 participants

May 27, 2026

Older news releases →

Decks in 2026